Stay updated with breaking news from Complete Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR, two-year local recurrence-free survival of 77%, and no...
BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc...
– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a...
Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment.